- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System
EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease
EP: 3.Genetic Aspects of Alzheimer Disease
EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease
EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease
EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing
EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease
EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
EP: 9.Clinical Decision-Making for Alzheimer Disease Management
EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease
EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease
EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Video content above is prompted by the following question(s):
- How might disease-modifying treatments for Alzheimer disease with different treatment duration and route of administration impact medical costs and caregiver burden?
Alzheimer Disease and Related Dementias Cause Surging Economic Burden for Minoritized Communities
June 5th 2025African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.
Read More
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
